Article
Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.
Molecular therapy : the journal of the American Society of Gene Therapy - 4 Mar 2026
Tebas Pablo, Jadlowsky Julie K, Zhou Yuqi, Pampena M Betina, Leslie George J, Liu Nan, Srivatsa Sriram, Maldini Colby R, Wang Jingxin, Tsang Chungdhak Jaming, Mohamed Ola, Romano Josephine, Haggarty Beth, Plesa Gabriela, Gaymon Avery L, Brennan Andrea L, Veloso Elizabeth, Levine Bruce L, Putt Mary E, Kulikovskaya Irina, Gonzalez Vanessa, Fraietta Joseph A, Betts Michael R, Hoxie James A, Riley James L
Abstract excerpt
Coupling the HIV fusion inhibitor C34 with CXCR4 (C34-CXCR4) protected CD4 T cells from all strains of HIV. Escape from C34-CXCR4 expression proved difficult, requiring more than 21 serial passages, mutations at conserved gp41 sites, and a complete loss of Vpu activity. A dose-escalation phase 1 clinical trial was performed in which up to 10 billion C34-CXCR4-expressing T cells were infused into people with HIV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.